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and biomarkers, we estimated the 5-year SCD risk (HCM 
Risk-SCD model). Patients were categorized as low (< 4%), 
intermediate (≥ 4–<6%) or high (≥ 6%) risk. In addition, risk 
categorization according to the ACC/AHA guidelines was 
performed. HighT2 was present in 27% (29/109). Patients 
with HighT2 were more often at an intermediate-high risk 
of SCD according to the European (28 vs. 10%, p = .032) 
and American guidelines (41 vs. 18%, p = .010) compared to 
those without HighT2. The estimated 5-year SCD risk of our 
cohort was 1.9% (IQR 1.3–2.9%), and projected SCD rates 
were higher in patients with than without HighT2 (2.8 vs. 
1.8%, p = .002). In conclusion, HCM patients with HighT2 
were more likely to be intermediate-high risk, with projected 
SCD rates that were 1.5 fold higher than in patients without 
HighT2. These pilot findings call for corroborative studies 
with more intermediate-high risk HCM patients and clinical 
follow-up to assess whether HighT2 may have additional 
value to current risk stratification.
Keywords Hypertrophic cardiomyopathy · 
Cardiovascular magnetic resonance imaging · Sudden 
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Introduction
Hypertrophic cardiomyopathy (HCM) is the most common 
inheritable cardiomyopathy and the most frequent cause of 
sudden cardiac death (SCD) among young athletes [1–3]. 
Unfortunately, identification of patients at risk of SCD 
remains challenging and new risk stratifiers such as biomark-
ers and imaging parameters are under investigation [4–8]. 
In this context, cardiovascular magnetic resonance (CMR) 
imaging is increasingly used for assessment of the extent 
Abstract In search of improved risk stratification in 
hypertrophic cardiomyopathy (HCM), CMR imaging has 
been implicated as a potential tool for prediction of sud-
den cardiac death (SCD). In follow-up of the promising 
results with extensive late gadolinium enhancement (LGE), 
high signal-intensity on T2-weighted imaging (HighT2) 
has become subject of interest given its association with 
markers of adverse disease progression, such as LGE, ele-
vated troponin and non-sustained ventricular tachycardia. 
In lack of follow-up cohorts, we initiated an exploratory 
study on the association between HighT2 and the interna-
tionally defined risk categories of SCD. In a cohort of 109 
HCM patients from a multicenter study on CMR imaging 
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of late gadolinium enhancement (LGE), as an indicator of 
fibrotic burden [6, 9, 10].
Another imaging feature with potential impact could 
be high signal intensity using T2-weighted CMR imaging 
(HighT2). This is based on the reported associations with 
markers of adverse disease progression, such as LGE, ele-
vated troponin, and non-sustained ventricular tachycardia 
[5, 6, 11–13].
Whereas LGE is observed in about 60–70% of patients, 
HighT2 is observed in about one-third of HCM patients. 
Notably, areas of HighT2 are almost exclusively present in 
patients with LGE, occurring within the boundaries of LGE 
[13–20]. Appreciating that the prevalence of intermediate-
high risk HCM patients is rather low, these specific charac-
teristics of HighT2 may allow for refined stratification.
In addition, we have recently reported an independent 
association with an elevated level of cardiac troponin T, 
which supports that HighT2 is likely indicative of recently 
sustained myocyte injury [20]. In view of this, HighT2 may 
identify patients with a more active disease state, who might 
be vulnerable to adverse disease progression. The additional 
observations that HighT2 was associated with NSVT raised 
the question whether HighT2 might be a valuable predictor 
of adverse events, SCD in particular [14, 16, 18].
Importantly, studies with clinical follow-up on HighT2 
are lacking. Therefore, we sought to provide the first pilot 
data on the association of HighT2 with the current SCD 
risk categorizations according to the ESC and ACC/AHA 
guidelines. We assessed the proportion of intermediate to 
high risk patients in relation to the presence or absence of 
HighT2. In addition, we performed an exploratory analysis 
on HighT2 and the associated projected SCD rates deter-
mined with use of the HCM Risk-SCD model, to provide 
insight into potential clinical implications [21].
Methods
Study population
For the present analysis, we studied a series of HCM patients 
who underwent T2-weighted CMR imaging, as participants 
of a Dutch multicentre HCM study project [20]. In short, 
enrollment took place between 2008 and 2014 at different 
outpatient clinics that perform mutation screening, repeated 
echocardiography, CMR imaging and clinical follow-up on 
a routine basis. Patients had to fulfill the diagnostic criteria 
for HCM according to the prevailing guidelines, which were 
assessed by a careful case-by-case chart review, especially 
in those with a history of hypertension [1, 2, 22]. Patients 
with known coronary disease or stroke, a history of out-
of-hospital cardiac arrest, aortic stenosis, previous septal 
reduction therapy, renal impairment (MDRD < 30 ml/min) 
or a contraindication for CMR imaging were excluded. The 
study complies with the Declaration of Helsinki and the 
protocol was approved by the local ethical committees and 
conducted accordingly. All participants provided written 
informed consent.
Cardiovascular magnetic resonance image acquisition 
and analysis
CMR imaging was performed on a 1.5T CMR system 
(Philips Achieva - Philips HealthCare, Best, The Nether-
lands or Siemens Avanto—Siemens Health Care, Erlan-
gen, Germany) according to local imaging protocols, as 
previously described in more detail [20]. All images were 
acquired with ECG-gating and during repeated breath-holds 
of 10–15 s. To assess the presence of HighT2, breath-hold 
triple inversion-recovery T2-weighted images with fat-
saturation were acquired (short-axis stack covering the left 
ventricle (LV) from base to apex). A long-axis image was 
obtained to exclude artifacts. For the assessment of LV func-
tion and mass, cine imaging was performed using a steady-
state free precession sequence (short-axis stack covering 
the LV from base to apex). Segmented inversion-recovery 
imaging was performed to assess late gadolinium enhance-
ment (LGE) 10 min after the administration of 0.2 mmol/
kg contrast medium (Dotarem; Guerbet, Gorinchem, The 
Netherlands).
Images were analyzed with commercially available 
software (QMass 7.5, Medis, Leiden, The Netherlands) by 
two observers (FG and JB) unaware of the subjects’ clini-
cal information. All 17 segments of the AHA-model were 
analyzed for the presence of HighT2 and LGE. HighT2 and 
LGE were scored visually per segment as either present or 
absent [15, 17]. In case of discrepancy between both observ-
ers on the presence of LGE or HighT2, a third observer (HD) 
reviewed the images for final adjudication. The observers 
were blinded for LGE data when analyzing T2-weighted 
images. The extent of LGE was determined according to a 
semi-quantitative score [23]. LV volumes, mass and ejection 
fraction were assessed using a standard protocol, as previ-
ously described [24, 25].
Assessment of sudden cardiac death risk
For all participants, the following risk factors were recorded 
at the day of CMR imaging: age at evaluation; family history 
of SCD; history of unexplained syncope; NSVT on 24-h 
Holter monitoring; maximal LV wall thickness, LV outflow 
tract obstruction gradient (either resting or provocable gra-
dient) and left atrial diameter measured using echocardiog-
raphy; abnormal blood pressure response during exercise. 
Missing data was ̴ 1%. For a detailed description and analy-
sis of the risk factors, we refer to the appendix.
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Our primary objective was to study the association 
between HighT2 and the categorization into low, interme-
diate or high risk of SCD according to the ESC and ACC/
AHA guidelines [1, 2]. For the former, the HCM Risk-SCD 
calculator was used for estimation of the 5-year SCD risk, 
available at http://doc2do.com/hcm/webHCM.html. An 
intermediate risk was defined as an estimated 5-year SCD 
risk of ≥ 4–< 6% and a high risk as ≥ 6% [1, 26]. Accord-
ing to the ACC/AHA guidelines, patients were considered 
high risk in case of a family history of SCD, a history of 
unexplained syncope or extreme LV hypertrophy. In case 
of an abnormal blood pressure during exercise or NSVT 
on 24-h Holter monitoring, patients were recorded as inter-
mediate or low risk depending on whether a risk modifier 
was present or not. Risk modifiers were a LV outflow tract 
gradient ≥ 30 mmHg or extensive LGE (≥ 15% of LV mass). 
Our secondary outcome measure was the estimated 5-year 
SCD risk as a continuous variable.
Statistical analysis
Continuous variables are presented as means ± standard 
deviations or medians [interquartile ranges (IQR)], and were 
compared between patients with and without HighT2 using 
a Student’s t or Mann–Whitney U test, whichever appro-
priate. Dichotomous variables were compared using a Chi 
square or Fisher exact test, whichever appropriate. Given 
the previously reported co-localization of HighT2 with LGE 
[20], we also compared SCD risk in relation to LGE sta-
tus, using a Kruskall-Wallis and Chi square test. A p value 
of < .05 was considered statistically significant. Statistical 
analysis was performed with IBM SPSS Statistics 20.0 (IBM 
Corp, Armonk, NY, USA).
Results
Study population
The present study population comprised of 109 HCM 
patients (56% male, age 54 ± 15), of whom the majority has 
previously been described [20]. 59 (58%) carried a patho-
genic sarcomere mutation and atrial fibrillation was present 
in 18 (17%) patients (Table 1). Most patients were a- or 
mildly symptomatic with 105 (96%) patients in NYHA class 
I–II.
Twenty-nine out of 109 (27%) were positive for HighT2. 
HighT2 was mostly observed midwall and co-localized 
within an area of LGE in hypertrophied segments, as previ-
ously described in more detail [20] (Fig. 1). In patients with 
HighT2, the median number of segments with HighT2 was 
3 (IQR 2–4).
Patients with HighT2 tended to be more dyspnoeic and 
had a higher LV mass indexed to body surface area and a 
Table 1  Baseline characteristics of HCM patients with and without HighT2
Data are presented as means ± standard deviations, medians (interquartile ranges) or numbers (percentages)
HighT2 high signal intensity on T2-weighted imaging, NYHA New York Heart association, CMR cardiovascular magnetic resonance, LV left 
ventricle, LVMI LV mass indexed to body surface area, LGE late gadolinium enhancement
Total (n = 109) HighT2 present (n = 29) HighT2 absent (n = 80) p value
Age (years) 54 ± 15 52 ± 14 55 ± 15 .29
Men 61 (56) 20 (69) 41 (51) .10
Age at diagnosis (years) 47 ± 16 44 ± 15 49 ± 16 .20
Pathogenic mutation present 59 (58) 15 (58) 44 (58) .99
Atrial fibrillation 18 (17) 5 (17) 13 (16) 1.0
Hypertension 40 (37) 9 (31) 31 (39) .46
Symptoms
 Chest pain 21 (19) 3 (10) 18 (23) .16
 Dyspnea (NYHA class ≥ II) 49 (45) 17 (59) 32 (40) .08
Therapy
 Beta-blocker 51 (47) 13 (45) 38 (48) .81
 Calciumantagonist 16 (15) 3 (10) 13 (16) .55
 Troponin T concentration (ng/L) 8 (3–14) 15 (8–25) 7 (3–12) < .001
CMR Imaging
 LVMI (g/m2) 62 (52–87) 85 (63–116) 59 (51–74) < .001
 LV ejection fraction (%) 59 ± 7 55 ± 7 61 ± 6 < .001
 LGE present (n) 68 (65) 26 (93) 42 (55) < .001
 LGE extent (% of LV mass) 3 (0–10) 10 (4–19) 1 (0–7) < .001
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lower LV ejection fraction. Furthermore, cardiac troponin 
T concentrations were higher in patients with than without 
HighT2. The proportion of patients with LGE and the extent 
of LGE were also higher in the former group (Table 1).
HighT2 and risk of sudden cardiac death
Patients with HighT2 were more often at an intermediate-
high SCD risk according to the ESC guidelines (28 vs. 10%, 
p = .032) and ACC/AHA guidelines (41 vs. 18%, p = .010) 
(Table 2; Fig. 2). Projected mortality rates were higher 
in patients with HighT2, with a median estimated 5-year 
SCD risk of 2.8 versus 1.8% for patients without HighT2 
(p = .002). The analysis on HighT2 combined with LGE 
status, demonstrated the lowest SCD risk in HCM patients 
without LGE and without HighT2. Moreover, in patients 
with LGE those with HighT2 had the highest SCD risk 
(Table 3).
Table 4 displays the prevalence of each of the respective 
risk factors and risk modifiers stratified for the presence of 
HighT2. In addition to the significantly higher maximal wall 
thickness in patients with HighT2, the numerically higher 
proportion of NSVT and younger age contributed to the 
higher estimated 5-year SCD risk in these patients. With 
regard to the ACC/AHA risk model, extensive LGE was 
significantly more often present in patients with HighT2. 
Among HCM patients with an estimated low risk of SCD 
according to the ESC guidelines (n = 93), those without 
HighT2 had a significantly lower SCD risk score than those 
with HighT2 (1.7 vs. 2.0%, p = .021). Among those with an 
estimated high risk of SCD (n = 5), those without HighT2 
(n = 3) had an estimated risk of SCD of 6.1, 6.2 and 6.9 vs. 
7.4 and 9.6% in those with HighT2 (n = 2) (Supplementary 
Fig. 1).
Discussion
This report represents a first exploratory analysis in the larg-
est HCM cohort so far on the association between HighT2 
and the risk categories for sudden cardiac death, as defined 
by the European and AHA/ACC guidelines.
Our pilot data demonstrate that HCM patients with 
HighT2 are more likely to be at intermediate to high risk of 
SCD, with projected SCD rates that are 1.5 fold higher than 
in patients without HighT2.
Importantly, apart from associations with some of the 
variables integrated in the HCM Risk-SCD model, HighT2 
was also found to be related to markers of adverse disease 
progression not incorporated in the model (extensive LGE, 
LV mass and LV ejection fraction). When these findings 
are confirmed in larger cohorts with a higher proportion of 
intermediate-high risk patients, HighT2 may prove to be a 
valuable additive risk modifier or risk factor for future risk 
stratification schemes.
With the increasing use of CMR imaging in HCM, tissue 
characterization has become a topic of interest to further 
Fig. 1  An imaging example of a HCM patient with HighT2. HighT2 
was mostly demonstrated as a focal area in the hypertrophied anter-
oseptal wall at the insertion point of the right ventricle, as displayed 
here
Table 2  SCD risk profile in HCM patients with or without HighT2
Data are presented as numbers (percentages) or medians (interquartile ranges)
HighT2 high signal intensity on T2-weighted imaging, SCD sudden cardiac death
Total (n = 109) HighT2 present (n = 29) HighT2 absent (n = 80) p value
Risk category
 ESC: Intermediate-high SCD risk 16 (15) 8 (28) 8 (10) .032
 ACC/AHA: Intermediate-high SCD risk 26 (24) 12 (41) 14 (18) .010
Quantitative SCD risk
 Estimated 5-year risk (%) 1.9 (1.3–2.9) 2.8 (1.6–4.3) 1.8 (1.2–2.6) .002
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Fig. 2  Risk categorization according to the ESC and ACC/AHA 
guidelines, stratified by the presence of HighT2. Left: according to 
the ESC guidelines, patients with HighT2 were more often at inter-
mediate to high risk: 28% (8/29) versus 10% (8/80), p = .032. Of the 
29 patients with HighT2, there were 21 at low risk of SCD; 6 and 2 
were at intermediate and high risk, respectively. Of the 80 patients 
without HighT2, there were 72 at low risk of SCD; 5 and 3 were at 
intermediate and high risk, respectively. Right: according to the ACC/
AHA guidelines, patients with HighT2 were more often at intermedi-
ate to high risk: 41% (12/29) versus 18% (14/80), p = .010. Of the 29 
patients with HighT2, there were 17 at low risk of SCD; 6 and 6 were 
at intermediate and high risk, respectively. Of the 80 patients without 
HighT2, there were 66 at low risk of SCD; 2 and 12 were at interme-
diate and high risk, respectively
Table 3  SCD risk profile in 
HCM patients with or without 
HighT2/LGE
Data are presented as numbers (percentages) or medians (interquartile ranges)
LGE late gadolinium enhancement, HighT2 high signal intensity on T2-weighted imaging, SCD sudden 
cardiac death
LGE− and 
HighT2− 
(n = 35)
LGE+ and 
HighT2− 
(n = 42)
LGE+ and 
HighT2+ 
(n = 26)
p value
Risk category
 ESC: intermediate-high SCD risk 1 (3%) 7 (17%) 8 (31%) .012
 ACC/AHA: intermediate-high SCD risk 5 (17%) 9 (21%) 11 (42%) .035
Quantitative SCD risk
 Estimated 5-year risk (%) 1.5 (1.1–1.9) 2.3 (1.4-3.0) 2.9 (1.6–4.3) < .001
Table 4  Individual risk factors 
and risk modifiers in HCM 
patients with or without HighT2
Data are presented as means ± standard deviations, medians (interquartile ranges) or numbers (percentages)
HighT2 high signal intensity on T2-weighted imaging, SCD sudden cardiac death, VT ventricular tachycar-
dia, BP blood pressure, LV left ventricle, LGE late gadolinium enhancement
Total (n = 109) HighT2 pre-
sent (n = 29)
HighT2 absent (n = 80) p value
Binary risk factors
 Family history of SCD 12 (11) 4 (14) 8 (10) .73
 Syncope 5 (5) 2 (7) 3 (4) .61
 Non-sustained VT 17 (16) 6 (21) 11 (14) .38
 Abnormal BP response 13 (12) 7 (24) 6 (8) .04
 Extreme LV hypertrophy 3 (3) 1 (3) 2 (3) 1.0
Continuous risk factors
 Age (years) 54 ± 15 52 ± 14 55 ± 15 .29
 Maximal wall thickness (mm) 17 (14–20) 19 (17–23) 16 (13–20) < .001
 Left atrial diameter (mm) 43 (39–50) 43 (40–54) 43 (39–48) .26
 LV outflow tract gradient (mmHg) 8 (6–23) 8 (5–21) 8 (6–25) .74
Risk modifiers
 LV outflow tract gradient ≥ 30 mmHg 21 (19) 5 (17) 16 (20) .75
 Extensive LGE (≥ 15% of LV mass) 10 (9) 8 (28) 2 (3) < .001
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unravel pathophysiological aspects of the disease, and to 
determine the additional contribution of these imaging fea-
tures in risk prediction of sudden death. From these studies 
we have learned that in almost all patients with HighT2 a 
substrate for arrhythmias was present in the form of fibrosis 
[13–20]. In addition, it has been demonstrated that the sym-
pathetic tone is higher in patients with HighT2 [18]. These 
observations may explain why HighT2 has previously been 
associated with the occurrence of NSVT [14, 16, 20]. In 
addition, association with other markers of advanced dis-
ease have been reported [18, 20]. In this context, it has been 
hypothesized that HighT2 might be a predictor of adverse 
events, SCD in particular.
In our HCM population, patients with HighT2 were 
more often at an intermediate-high SCD risk, regardless 
of whether the European or Northern American guidelines 
were used. It is evident that in the large subset of our low risk 
HCM patients, projected SCD rates were significantly higher 
in patients with HighT2. Whether this can be extrapolated 
to intermediate-high risk patients remains to be determined.
On the one hand, it should be noted that this observed 
association may be confounded due to the association 
between HighT2 and some of the conventional risk factors 
[LV wall thickness in particular (Table 4)]. In addition, the 
predictive value of HighT2 does not seem to be high. How-
ever, it has repeatedly been demonstrated that the discrimi-
native ability of the individual risk factors of the models 
is rather poor, and that it is the combination of factors that 
improves the predictive ability.
On the other hand, HighT2 was also associated with the 
risk modifier extensive LGE (ACC/AHA) and other indica-
tors of disease severity such as higher LV mass, lower LV 
ejection fraction and higher troponin T concentration [5, 6, 
9, 11, 27, 28]. These results suggest that HighT2 is not a 
mere surrogate marker of risk factors already included in the 
prevailing risk models, but might be a valuable composite 
marker of arrhythmic risk, that would otherwise remain con-
cealed with the current risk stratification schemes. Notably, 
fibrosis may be a confounder for HighT2 in the prediction 
of SCD. However, among those with fibrosis, we have dem-
onstrated that the patients with HighT2 were more often at 
an intermediate-high risk of SCD. These findings are sup-
portive evidence to conduct larger studies on the potential 
impact of HighT2 in relation to LGE and the conventional 
risk factors.
Potential impact of HighT2 on clinical practice
The observed 1.5 fold risk increase for SCD associated with 
HighT2 is in the same order of magnitude as observed for an 
extent of LGE of ≥ 15%, which is associated with an almost 
twofold increased risk [6, 9].
Based on our findings, several hypotheses for both low 
risk and intermediate-high risk patients could be addressed 
in future studies as potential implications. Our findings in 
the large group of low risk patients imply that T2-weighted 
CMR imaging might be able to increase the negative predic-
tive value of current risk stratification schemes. At present, 
sudden cardiac death still occurs among low risk patients, 
and because of the high proportion of low risk patients in 
the general HCM population absolute numbers of cases with 
SCD are still considerable [29]. In the absence of HighT2, 
we may identify a subgroup of low risk patients, who are 
really at very low SCD risk. This could implicate that they 
could reliably be assured that SCD is highly unlikely to 
occur [30].
As for the impact of HighT2 in intermediate-high risk 
patients, the small sample size does not allow firm conclu-
sions. Possibly, the presence or absence of HighT2 could 
help to differentiate between higher and lower risk patients, 
respectively. As for the former, we demonstrated associa-
tions with indicators of advanced disease, such as low ejec-
tion fraction and troponin. Moreover, our data suggest that 
HighT2 seems to differentiate among patients with LGE.
It should be acknowledged that approximately half of the 
patients at intermediate-high risk did not have HighT2. This 
may be interpreted as an undesirable “missing” of patients 
at a considerable estimated risk of SCD. However, it has 
been demonstrated in an independent validation cohort for 
the HCM-SCD risk model that with a SCD rate of around 
5%, about 17 patients need an ICD implantation to prevent 
one SCD in 5 years [31]. In addition, it was demonstrated 
that, especially in high risk patients, the predicted SCD risk 
was higher than the observed SCD risk [31]. Consequently, 
in the majority of HCM patients at an estimated interme-
diate-high risk no SCD occurs and ICD implantation may 
preferentially have been avoided. It requires further study to 
investigate whether the absence of HighT2 in intermediate-
high risk HCM patients may lower the odds of future SCD, 
and improve the number needed to treat to prevent one SCD.
Future developments: an integrative CMR approach
In search of refinement of the current risk stratification 
models that are based on echocardiographic and clinical 
variables, we agree with European and Northern American 
experts that incorporating myocardial tissue characteriza-
tion (LGE and HighT2) may be of additional value [32–35].
The positive predictive value of the mere presence of 
LGE proved to be limited by its prevalence of about 60–70% 
and the annual risk of SCD of only about 1% in a general 
HCM population. In response, the extent of LGE has become 
the topic of interest, with promising results in risk predic-
tion [6, 9, 36]. Of interest, extensive LGE was more often 
present in patients with HighT2. However, more than half 
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of the cases with HighT2 were observed in patients without 
extensive LGE. Inherently, there may be additional value for 
HighT2, which is also confirmed by our finding that among 
LGE positive patients those with HighT2 had the highest 
estimated SCD risk.
Previously, we have demonstrated that among HCM 
patients with LGE, those without HighT2 had the lowest 
troponin concentration, resembling that of patients without 
any LGE. Moreover, patients without HighT2 had a nine-
fold lower chance of extensive LGE. Whereas the number of 
intermediate-high risk patients is limited, our findings in the 
large cohort of low risk patients are more robust and imply 
that it is likely that the absence of HighT2 could improve the 
negative predictive value in these patients.
In summary, given the currently suboptimal risk stratifi-
cation, the addition of HighT2 may be valuable to improve 
both negative and positive predictive values of the risk mod-
els.. Incorporation of the abovementioned CMR variables 
in (currently running) HCM follow-up studies may provide 
valuable information with regard to their independent asso-
ciation and additive predictive values [7, 8].
Limitations
Although this is the largest cohort of HCM patients with 
T2-weighted imaging information, the main limitation of 
this study is the low risk profile of the study population. At 
the time of this study 5-year follow-up was available for 70% 
of our cohort. With projected 5-year follow-up rates of about 
2%, we decided that clinical endpoints rather than estimated 
sudden death rates would not provide much additional value 
for the current study question.
In this context, we performed exploratory analyses on 
projected rates of SCD and our findings should therefore 
be considered as hypothesis generating, and do not validate 
HighT2 as a risk factor for SCD. Confirmative studies with 
clinical follow-up in a more intermediate-high risk popula-
tion are warranted.
Furthermore, the technique under investigation is limited 
by a high signal-to-noise ratio and frequent artifacts. Unfor-
tunately, T2-mapping sequences were not available at the 
start of our study, but these seem very promising and may 
lead to more objective data. In analogy to previous studies 
in HCM, the presence of HighT2 was visually assessed by 
two independent observers (FG and JB) [15, 17]. A third 
observer was required for final adjudication in 14 of 109 
patients (Cohen’s kappa: 0.631, p < .001). Regardless of 
whether results of observer 1 or 2 were used, the differences 
in SCD risk between patients with and without HighT2 were 
consistent.
Lastly, we are well aware of the fact that the validity of 
the HCM Risk-SCD model has recently been challenged for 
Northern American patients [37]. Nonetheless, for the cur-
rent analysis, the HCM Risk-SCD model has the advantage 
of quantification of projected risk of SCD.
Conclusion
In an era where tissue characterization with CMR imaging 
has become topic of interest for SCD risk stratification, we 
are the first to demonstrate that HCM patients with HighT2 
are more likely to be at intermediate to high risk of SCD, 
with projected SCD rates that are 1.5 fold higher than in 
patients without HighT2. Notably, HighT2 was not only 
associated with established risk factors, but also with several 
markers of a detrimental disease course, that are currently 
not incorporated in the HCM Risk-SCD model.
The present findings should be considered as “pilot data”, 
but do put forward the hypothesis that HighT2 might be 
valuable for future SCD risk stratification models in HCM.
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